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ORIGINAL ARTICLE
Having co-morbid cardiovascular disease at time of cancer diagnosis: already
one step behind when it comes to HRQoL?
Dounya Schoormansa , Olga Hussonb , Simone Oerlemansc , Nicole Ezendamc and Floortje Molsa
aCoRPS – Center of Research on Psychological and Somatic Disorders, Department of Medical and Clinical Psychology, Tilburg University,
Tilburg, The Netherlands; bDepartment of Psychosocial and Epidemiological Research, Netherlands Cancer Institute, Amsterdam, The
Netherlands; cComprehensive Cancer Organisation, Eindhoven, The Netherlands
ABSTRACT
Background: The relation between cardiovascular disease (CVD) present at the time of cancer diagno-
sis and Health-Related Quality of Life (HRQoL) assessed years after cancer diagnosis has – to our know-
ledge – not been studied. The objective is, therefore, to examine the relation between co-morbid CVD
at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate,
endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia
(CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study.
Material and methods: Analyses were performed on combined data sets from the PROFILES and
Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from
the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer diagnosis. General
Linear Model Analyses were run for the total group of cancer survivors and for each malignancy.
Results: In total, 5930 cancer survivors (2281 colorectal, 280 thyroid, 1054 prostate, 177 endometrium,
389 ovarian cancer, 212 melanoma, 874 non-Hodgkin and 194 Hodgkin lymphoma, 242 CLL, and
227MM survivors) were included. For the total group, survivors who had a CVD at cancer diagnosis
(n¼ 1441, 23.4%) reported statistically significant and clinically important lower scores on global QoL
and physical functioning and higher scores for dyspnea (p< .05) compared to those without CVD. Co-
morbid CVD at cancer diagnosis was negatively related to global QoL, the five functional scales and
the symptoms fatigue and dyspnea across most malignancies (i.e., colorectal, and prostate cancer,
non-Hodgkin lymphoma, ovarium cancer, melanoma, and CLL). No significant relations were found
among thyroid and endometrium cancer, Hodgkin lymphoma and MM survivors, likely due to
small numbers.
Conclusion: In conclusion, co-morbid CVD at cancer diagnosis was negatively related to HRQoL, espe-
cially to global QoL, physical and role functioning, and the symptoms fatigue and dyspnea.
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Introduction
Cancer and cardiovascular disease (CVD) are two common
causes of morbidity and mortality worldwide. It is estimated
that 20–30% of patients with cancer already have a co-morbid
CVD at the time of their cancer diagnosis [1]. Having a preex-
isting CVD often affects cancer treatment options, frequently
resulting in less aggressive treatment [2]. Alternatively, CVD’s
are well-known late effects of cancer treatment [3,4]. There is
increasing attention for the co-occurrence of CVD and cancer.
The International CardiOncology Society advocates that both
clinical practice and research should re-focus from a disease-
specific approach to a whole person approach – taking into
account information on both cancer and CVD [5]. This
approach is necessary to reduce the impact of CVD among
cancer survivors.
Within the field of oncology, there has been increasing
awareness for long-term outcomes including patient-
reported outcomes (PROs) such as Health-Related Quality of
Life (HRQoL). The presence of CVD in cancer survivors has
been negatively associated with patients’ clinical health out-
comes, such as survival [6]. Additionally, having one or more
co-morbid conditions at the time of HRQoL assessment
among cancer survivors has a negative impact on HRQoL
[7,8]. The relation between CVD present at the time of cancer
diagnosis and HRQoL assessed years after cancer diagnosis
has – to our knowledge – not been studied. The objective of
this study is, therefore, to examine the relation between co-
morbid CVD at cancer diagnosis and HRQoL among long-
term cancer survivors diagnosed with colorectal, thyroid,
prostate, endometrium, or ovarian cancer, melanoma, (non-
)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or
multiple myeloma (MM). Data were analyzed for the total
group of cancer survivors and for each malignancy separ-
ately. We hypothesize that those cancer survivors who had a
co-morbid CVD at cancer diagnosis experienced a poorer
HRQoL. Additionally, we examined whether the relation
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between co-morbid CVD and HRQoL differed by gender, age,
time since diagnosis, systemic therapy, radiation or hor-
mone treatment.
Material and methods
Study design and setting
This study uses data from the PROFILES (‘Patient Reported
Outcomes Following Initial treatment and Long term
Evaluation of Survivorship’) and Netherlands Cancer Registry
(NCR) [9]. The PROFILES registry is an ongoing data collection
of PROs within the sampling frame of the NCR and can be
linked with clinical data of all individuals newly diagnosed
with cancer in the Netherlands[9].
Study population
The current study combined several cohorts from the
PROFILES registry; i.e., survivors of colorectal, thyroid, pros-
tate, endometrium, and ovarian cancer, melanoma, (non-
)Hodgkin lymphoma, CLL, or MM as primary cancer [10].
Survivors were included during 2008–2014. Eligible partici-
pants were 18 years at cancer diagnosis and excluded if
they were not able to complete the questionnaire according
to their (ex-)attending specialist (i.e., due to severe cognitive
impairments, being too ill or those who were not sufficiently
flued in Dutch). Ethical approval was obtained for all study
samples separately, from local Dutch certified medical eth-
ics committees.
Data collection
Description of the data collection has been described previ-
ously [9]. In short, cancer survivors were informed about the
study via a letter by their (ex-)attending specialist. This letter
contained an informed consent form and a paper question-
naire or a secured link to a web-based informed consent
form and an online questionnaire. Patients could return a
postcard to request a paper-and-pencil questionnaire. For
each participant informed consent was obtained.
Measures
Co-morbid CVD
Data on co-morbid CVD at cancer diagnosis has been
extracted from medical records by trained registry personnel
and was registered in the NCR. Co-morbidity data have been
recorded since 1993 by screening previous admissions, let-
ters of referral from and discharge to general practitioners,
the medical history, current medication and preoperative
assessments [11]. Internal validation studies were performed
evaluating the quality by randomly checking completeness
and accuracy of the registry personnel extracting co-morbid-
ity information from the medical records [12]. The quality of
this data is high because of thorough training of the regis-
trars and computerized consistency checks at regional and
national level. Completeness is estimated to be at least 95%
[12]. CVDs were classified into: myocardial infarction; angina
pectoris; coronary artery disease; cardiac decompensation
(heart failure); cardiomyopathy; valve problems; heart trans-
plant; problems with heart rhythm; peripheral arterial dis-
ease; thrombosis; and cerebrovascular disease.
Health-Related quality of life (HRQoL)
HRQoL was measured by the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30) [13]. This 30-item question-
naire comprises five functional scales: physical, role, cogni-
tive, emotional and social functioning; a global quality of life
scale; three symptom scales on fatigue, pain, and nausea/
vomiting; and six items assessing dyspnea, insomnia, loss of
appetite, constipation, diarrhea and financial impact. A
higher score on the functional scales and global QoL means
better functioning and HRQoL, whereas a higher score on
the symptom scales indicates more complaints.
Socio-demographics and clinical characteristics
Age at diagnosis and gender were obtained from the NCR.
Patients’ marital status and educational level were assessed
via questionnaire.
The clinical characteristics of cancer stage and primary treat-
ment were obtained from the NCR. Cancer stage was classified
according to TNM [14] or Ann Arbor Code for (non-)Hodgkin
lymphoma. Primary treatment was classified into surgery, sys-
temic therapy (chemotherapy, targeted therapy, and immune
therapy), radiotherapy (including brachytherapy), and hormone
treatment. Number of co-morbidities other than CVD at the
time of survey was assessed with the adapted Self-adminis-
tered Co-morbidity Questionnaire (SCQ) [15] and categorized
into 0 co-morbidity, 1 co-morbidity or 2 co-morbidities.
Statistical analyses
Socio-demographics and clinical characteristics of those with
versus those without co-morbid CVD at cancer diagnosis
were compared by means of chi-square or t-tests. We exam-
ined the relation between having a co-morbid CVD at cancer
diagnosis and HRQoL by means of linear regression analyses
using the general linear model (GLM). Analyses were run for
the total group of cancer survivors and for each malignancy
separately. We included global QoL and the five functional
scales, together with the symptoms of fatigue and dyspnea,
as these are known to be impacted by CVD. Gender, age,
time since diagnosis, and undergoing systemic therapy, radi-
ation or hormone treatment are known to be related to co-
morbid CVD and/or HRQoL [3,4,6,16]. We therefore examined
whether the relation between co-morbid CVD at cancer diag-
nosis and HRQoL differed by gender, age (65 vs. >65), time
since diagnosis (0–5 years vs. >5 years), systemic therapy,
radiation or hormone treatment by adding interaction terms
(CVDgender/age/time since diagnosis/systemic therapy/radi-
ation/hormone treatment) together with their main effects to
the model.
ACTA ONCOLOGICA 1685
All these tests were two-sided and statistically significant
if p< .05. We conducted exploratory multiple tests for the
total sample of cancer survivors and in smaller subsamples
for each malignancy separately. Therefore we did not choose
to use a more stringent p-value of .01. Clinically meaningful
differences for the EORTC QLQ-C30 were determined using
EORTC guidelines, which were developed by a systematic
review of 152 cancer-specific articles, expert opinions, and
meta-analyses [17]. These EORTC guidelines classify four
groups: Trivial, circumstances unlikely to have any clinical
relevance or where there was no difference; Small, subtle but
nevertheless clinically relevant; Medium, likely to be clinically
relevant but to a lesser extent; Large, one representing
unequivocal clinical relevance [17]. Analyses were performed
using IBM SPSS V24.0.
Results
Socio-demographics, clinical characteristics, and co-
morbid CVD
In total, 5930 cancer survivors were included, with a median
age of 61 years at cancer diagnosis, where little over half was
male (n¼ 3421, 57.7%), Table 1. Nearly a quarter (n¼ 1441,
24.3%) had a co-morbid CVD at cancer diagnosis. Most
prevalent CVD’s for the total group of 503 (8.5%) cancer sur-
vivors were a myocardial infarct, angina pectoris, or coronary
artery disease. The second category was having cardiac
arrhythmias with 272 (4.6%) cancer survivors. Thirdly, 183
(3.1%) of cancer survivors had a co-morbid peripheral arter-
ial disease.
Cancer survivors with co-morbid CVD were more often
male, older and had a lower educational level, were less
often treated with surgery, systemic therapy and radiation,
received more often hormonal treatment, had a shorter fol-
low-up time (i.e. time between cancer diagnosis and HRQoL
measurement) and reported more co-morbidities compared
to those without CVD.
The sample of 5930 cancer survivors consisted of 2281
colorectal, 280 thyroid, 1054 prostate, 177 endometrium, 389
ovarian cancer, 212 melanoma, 874 non-Hodgkin lymphoma,
194 Hodgkin lymphoma, 242 CLL, and 227MM survivors [10].
CVD’s are most common among prostate (27.8%), CLL (26%),
MM (21.7), non-Hodgkin lymphoma (20.3%), and colorectal
cancer survivors (20.2%).
Table 1. Socio-demographics and clinical characteristics stratified by CVD status.
Total (n¼ 5930) CVD (n¼ 1441) No CVD (n¼ 4489)
Socio-demographics
Gender (m) 3421 (57.7) 851 (73.9) 2544 (54.7)
Median age at diagnosis 61 (18–88) 68 (34–88) 59 (18–88)
Married/co-habiting 4584 (78.2) 890 (78.8) 3603 (78.2)
Educational level
Low 958 (16.4) 242 (21.4) 695 (15.2)
Intermediate 3561 (61.0) 674 (59.5) 2799 (61.1)
High 1322 (22.6) 217 (19.2) 1085 (23.7)
Clinical characteristics
Cancer stagea
I 1635 (30.8) 291 (28.3) 1289 (31.0)
II 1851 (34.9) 372 (36.1) 1454 (35.0)
III 1262 (23.8) 246 (23.9) 991 (23.8)
IV 554 (10.4) 121 (11.7) 425 (10.2)
Treatment
Surgery 3622 (61.1) 613 (53.2) 2910 (62.6)
Systemic therapy 2013 (33.9) 349 (30.3) 1627 (35.0)
Radiation 1740 (29.3) 309 (26.8) 1392 (29.9)
Hormone treatment 319 (5.4) 103 (8.9) 212 (4.6)
Time since diagnosis
Median years (sd) 4.6 (3.1) 3.2 (2.4) 4.7 (3.2)
0–1 year 603 (10.2) 113 (9.8) 441 (9.5)
2–5 years 3451 (58.4) 779 (67.6) 2628 (56.8)
6–10 years 1629 (27.6) 249 (21.6) 1351 (29.2)
11 years 226 (3.8) 11 (1.0) 207 (4.5)
Co-morbidities
0 2620 (44.2) 396 (34.4) 2156 (46.4)
1 1740 (29.3) 359 (31.2) 1345 (28.9)
2 1570 (26.5) 397 (34.5) 1147 (24.7)
Malignancy
Colorectal 2281 (38.5) 454 (20.2) 1793 (79.8)
Thyroid 280 (4.7) 15 (5.4) 261 (94.6)
Prostate 1054 (17.8) 291 (27.8) 756 (71.7)
Endometrium 177 (3.0) 28 (20.0) 112 (80.0)
Ovarian 389 (6.6) 46 (12.5) 322 (87.5)
Melanoma 212 (3.6) 20 (9.7) 187 (90.3)
Non-Hodgkin lymphoma 874 (14.7) 175 (20.3) 688 (79.7)
Hodgkin lymphoma 194 (3.3) 12 (6.3) 179 (93.7)
CLL 242 (4.1) 63 (26.0) 177 (73.8)
MM 227 (3.8) 48 (21.7) 173 (78.3)
Socio-demographic and clinical characteristics in numbers (percentages) and age in median years (range). p< .05; aStage was missing for 10.6% as for CLL and
MM stage was undetermined/unregistered.
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Co-morbid CVD and HRQoL
Total group
Cancer survivors who had a CVD at cancer diagnosis
(n¼ 1441, 24.3%) reported significantly lower scores on glo-
bal QoL and all functional scales, with more symptoms of
fatigue and dyspnea (all p < .05) compared to those without
CVD (Figure 1). Differences in global QoL, physical function-
ing and dyspnea were of small clinical importance. The
remaining HRQoL scales differences were significant yet of
trivial clinical importance. Furthermore, the following socio-
demographic and clinical characteristics were related to
poorer global QoL and functioning, and more symptoms of
fatigue and dyspnea: female gender, not being married or
co-habiting, lower education, more co-morbidities, shorter
time after diagnosis, and higher tumor stage. Older age was
related to poorer physical functioning and more symptoms
of fatigue, yet better global QoL and emotional, cognitive
and social functioning.
Malignancy specific
The associations between co-morbid CVD at cancer diagnosis
and HRQoL for each of the ten malignancies are presented
in Table 2. To ensure sufficient power, effect modifications
for gender, age, time since diagnosis and cancer treatment
were performed in the three largest cancer survivor cohorts
in which the prevalence of CVD was high enough: colorectal
(n¼ 2281, n¼ 454 with CVD), prostate (n¼ 1054, n¼ 291
with CVD) and non-Hodgkin lymphoma survivors (n¼ 874,
n¼ 175 with CVD).
Colorectal cancer
Colorectal cancer survivors with a co-morbid CVD at cancer
diagnosis (n¼ 454, 20.2%) reported significantly lower scores,
which were of small clinical important difference, on physical
functioning (B¼6.89) and dyspnea (B¼ 5.75), all p< .05.
Additionally, statistically significant yet difference of trivial
clinical importance was found for global QoL (B¼3.54),
QoL**b PF**b RF**a EF*a CF*a SF**a FA**a DY**b
No CVD 74,67 79,09 77,62 82,66 82,78 84,46 27,25 16,47












Figure 1. Differences in HRQoL among those with and without CVD at cancer diagnosis for all survivors combined. Note: p< .05, p< .01. a: trivial; b: small; c:
medium clinically important difference. QoL: global QoL; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF:
social functioning; FA: fatigue; DY: dyspnea. Controlling for age, gender, marital status, education, stage, time since diagnosis, and co-morbidities.
Table 2. Unstandardized beta’s of linear regression analyses associating co-morbid CVD at cancer diagnosis with HRQoL scales specified for each malignancy.
QoL FP RF EF CF SF FA DY
Colorectal 3.54a 6.89b 3.51a 1.71 1.69 2.01 2.63a 5.75b
Thyroid 4.23 7.95 6.48 3.88 7.24 8.51 3.48 11.05
Prostate 4.67b 6.77b 7.20b 1.46 1.75 4.18a 5.05b 8.26b
Endometrium 4.34 0.67 5.11 5.72 0.07 1.74 2.62 1.91
Ovarian 4.35 0.31 6.78 4.25 2.67 0.88 2.57 8.50b
Melanoma 4.44 0.31 4.22 0.13 8.46b 0.18 1.90 0.77
Non-Hodgkin lymphoma 3.71a 6.29b 5.94a 1.00 1.88 1.66 4.11 11.58c
Hodgkin lymphoma 1.73 2.27 4.14 0.10 8.96 4.66 2.56 7.91
CLL 9.03b 13.80b 10.58b 7.58b 0.22 9.24b 10.42b 7.02
MM 2.16 7.34 8.14 3.79 0.20 1.91 2.99 2.86
QoL: global QoL; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; DY: dys-
pnea. Higher score on the global QoL and functional scales means better functioning and HRQoL, whereas a higher score on the symptom scales fatigue and
dyspnea means more complaints; p< .05, p< .01. atrivial; bsmall, cmedium clinically important difference. Controlling for age, gender, marital status, educa-
tion, stage, time since diagnosis, and co-morbidities.
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role functioning (B¼3.51) and more symptoms of
fatigue (B¼ 2.63).
There was a significant age-interaction effect for physical
functioning (B¼6.63 p< .01). Stratified analysis showed that
the negative relation between having a co-morbid CVD and
physical functioning was stronger for older CRC survivors
(B¼8.69, p< .01) than for younger CRC survivors
(B¼5.30, p< .01). Additionally, for role functioning a
significant interaction term was found for systemic therapy
(B¼ 5.63, p< .01), where the negative relation between
having a co-morbid CVD and role functioning was limited to
the group of survivors who were not treated with systemic
therapy (B¼4.26, p¼ .01). There were no significant
interaction effects for gender, radiotherapy or time since diag-
nosis (p> .05).
Prostate cancer
Prostate cancer survivors with co-morbid CVD at cancer diag-
nosis reported lower scores of small clinical importance on
global QoL (B¼4.67), physical (B¼6.77) and role func-
tioning (B¼7.20), and higher scores on fatigue (B¼ 5.06)
and dyspnea (B¼ 8.26) compared to those without CVD
(p< .01). Additionally a significant but clinically trivial relation
was found between having co-morbid CVD and social func-
tioning (B¼4.18).
Significant age-interaction effects were found for global QoL
(B¼ 6.17, p¼ .02) and emotional functioning (B¼ 6.48, p¼ .02).
There was a significant negative relation between having co-
morbid CVD on global QoL and on emotional functioning,
which was limited to younger prostate cancer survivors (global
QoL: B¼8.54, p< .01 and emotional functioning: B¼5.93,
p< .01). There were no significant interaction effects for radio-
therapy or time since cancer diagnosis.
Non-Hodgkin lymphoma
A small clinically important difference was found for physical
functioning (B¼6.29, p< .01), with lower scores for those
who had co-morbid CVD. Non-Hodgkin lymphoma survivors
with CVD reported more symptoms of dyspnea (B¼ 11.58,
p< .01), which was of medium clinical importance.
Furthermore, two significant but clinically trivial differences
were found; non-Hodgkin lymphoma survivors with co-mor-
bid CVD at cancer diagnosis reported lower scores for global
QoL (B¼3.71) and role functioning (B¼5.94), p< .05.
The relation between having a co-morbid CVD at cancer
diagnosis and the symptom dyspnea differed by gender
(interaction B¼ 9.90, p¼ .03), as there was only a significant
positive relation among females (B¼ 16.98, p< .01).
Additionally, the relation between having co-morbid CVD
and global QoL differed by being treated with radiotherapy
or not (interaction B¼ 9.90, p¼ .03). Stratified analyses
showed that co-morbid CVD was only significantly related to
global QoL among those who were treated with
radiotherapy (B¼12.07, p< .01). No significant interaction
effects for age, systemic therapy or time since diagnosis
were found (p> .05).
Ovarian cancer
Ovarian cancer survivors with co-morbid CVD at cancer diag-
nosis reported more symptoms of dyspnea (B¼ 8.50, p¼ .03),
which was of small clinical importance.
Melanoma
A small clinically significant effect was found, with lower
scores on cognitive functioning (B¼8.46, p¼ .03) among
melanoma survivors who had co-morbid CVD at can-
cer diagnosis.
CLL
CLL survivors with a co-morbid CVD at cancer diagnosis
reported small clinically important lower scores on global
QoL (B¼9.03), physical (B¼13.80), role (B¼10.58),
emotional (B¼7.58), and social functioning (B¼9.24), yet
higher scores on symptoms of fatigue (B¼ 10.42) (all p< .05).
Thyroid and endometrium cancer, Hodgkin lymphoma
and MM
No significant relations between co-morbid CVD at cancer
diagnosis and HRQoL were seen among thyroid, endomet-
rium, Hodgkin lymphoma, and MM survivors.
Discussion
Of the total sample of cancer survivors (n¼ 5930), 24.3%
(n¼ 1441) had a co-morbid CVD at the time of their cancer
diagnosis. A co-morbid CVD-diagnosis was most common
among prostate (27.8%), CLL (26%), MM (21.7), non-Hodgkin
lymphoma (20.3%), and colorectal cancer survivors (20.2%).
Overall, cancer survivors with co-morbid CVD were more
often male, older and had a lower educational level, received
less often treatment (surgery, systemic therapy, and radi-
ation, yet more often hormonal treatment), and reported
more other co-morbidities compared to those without CVD.
For the total group, survivors with CVD at cancer diagno-
sis reported statistically and clinically significant lower scores
on global QoL and physical functioning and higher scores
for dyspnea (p< .05) compared to those without CVD.
Among colorectal, prostate, ovarian cancer, non-Hodgkin
lymphoma and CLL survivors, those with a co-morbid CVD at
cancer diagnosis reported small clinically relevant lower
scores on global QoL, physical and role functioning and
more symptoms of fatigue and dyspnea. This finding is con-
sistent with studies among CVD patients, often experiencing
impairments in global QoL, physical and role functioning
[18,19]. Furthermore, fatigue and dyspnea are known to be
key symptoms of various CVDs [20]. Additionally, survivors
with co-morbid CVD at cancer diagnosis reported worse
emotional (CLL), social (prostate and CLL), and cognitive
functioning (melanoma). As CLL cannot be cured and follow-
ing guidelines treatment options are highly dependent on
overall health, having a co-morbid CVD at cancer diagnosis
could result in impairments in emotional and social function-
ing. A well-known long-term problem among prostate cancer
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survivors is incontinence which has a negative impact on
social functioning [21]. Common treatment among CVD
patients are diuretics to reduce strain on the heart by
increasing urine production. This could explain why prostate
cancer survivors with a co-morbid CVD at cancer diagnosis
report lower social functioning. Reduced cognitive function-
ing among melanoma survivors is understandable as these
cancer survivors suffered from vascular CVDs often located in
the brain such as a cerebrovascular accident as stated in the
NCR (data not shown). No significant relations between co-
morbid CVD and HRQoL were found among thyroid and
endometrium cancer, Hodgkin lymphoma and MM survivors.
This could be due to the small number of survivors with co-
morbid CVD (thyroid (n¼ 15), endometrium (n¼ 28) cancer,
Hodgkin lymphoma (n¼ 12), and MM (n¼ 48)).
Among non-Hodgkin lymphoma survivors, the relation
between having co-morbid CVD and symptoms of dyspnea
was limited to women. This is in line with the clinical presen-
tation, as dyspnea is a typical symptom displayed and
reported by women [22]. However, this gender effect was
not seen among colorectal cancer survivors. Age-modification
effects were seen among colorectal and prostate cancer sur-
vivors. That is, the negative relation between co-morbid CVD
at cancer diagnosis and physical functioning was stronger
among older colorectal cancer survivors (>65 years).
Contrary, only younger prostate cancer survivors (65 years)
reported lower global QoL and emotional functioning when
they had a co-morbid CVD at cancer diagnosis. This is in line
with general findings relating older age to poorer physical
functioning [23], and younger age to poorer emotional func-
tioning [24]. Additionally, the effect of co-morbid conditions
at younger age may have a stronger impact on global QoL
than among older survivors. This could be because overall
HRQoL decreases due to aging and the development of co-
morbid conditions is somewhat expected and similar to their
non-cancer peers. Additionally, younger survivors have more
competing responsibilities, hence the negative relation
between co-morbid CVD and HRQoL is more severe as has
been previously described [8].
The negative relation of having co-morbid CVD at cancer
diagnosis and role functioning was limited to colorectal can-
cer survivors who were not treated with systemic therapy.
Systemic treatment can have serious long-term adverse
effects [25] and is known to have a negative impact on
HRQoL. In the case of both having a co-morbid CVD and
being systemically treated for cancer, the impact of having
co-morbid CVD at cancer diagnosis may be secondary to the
negative impact of systemic treatment when it comes to
HRQoL. In other words, only when the impact of systemic
treatment on HRQoL is excluded, one sees a negative rela-
tion between having a co-morbid CVD and HRQoL. Non-
Hodgkin lymphoma survivors with co-morbid CVD at cancer
diagnosis reported lower global QoL, only if they were
treated with radiotherapy. It could be that among non-
Hodgkin lymphoma survivors with co-morbid CVD, radiation
to the chest leads to an increase in cardiovascular prob-
lems[3,4], especially among those who had preexisting CVDs.
In turn this could negatively impact their global QoL.
Examined among colorectal, non-Hodgkin lymphoma, and
prostate cancer survivors we found that the negative relation
between having a co-morbid CVD at cancer diagnosis and
HRQoL was not related to the timing of the HRQoL question-
naire. This is inconsistent with a previous study among
breast cancer survivors, where the relation between co-mor-
bidities present at the time of the assessment and HRQoL
was stronger when the cancer diagnosis was longer ago [8].
In the current study, we have no information on date of CVD
diagnosis only whether cancer survivors have a co-morbid
CVD at cancer diagnosis. Hence, it is unclear how relevant
the co-morbid CVD is when it comes to HRQoL at the time
of the HRQoL-assessment often years later. The data did
include information on whether cancer survivors were diag-
nosed with a secondary cancer during follow-up. We, there-
fore, performed sensitivity analyses examining the relation
between co-morbid CVD at cancer diagnosis and HRQoL for
this subgroup (n¼ 1100, 18.5%). Results showed similar
regression coefficients as for the total group of survivors, yet
some associations became non-significant which is likely due
to reduced power (data not shown).
The following study limitations should be taken into
account. No information is available on the severity of co-
morbid CVD. Additionally, we do not have information on
the development of new CVDs during follow-up or whether
CVDs have worsened. Moreover, by virtue of remaining dis-
ease-free, long-term cancer survivors have a better prognosis,
may have received less aggressive treatment likely resulting
in a better HRQoL. Furthermore, the sample selection may
have biased our results as non-respondents are more often
male, younger (<60) or older (>70), have a lower socioeco-
nomic status, received less often radiotherapy or no treat-
ment and reported fewer co-morbidities [10]. Finally, we
have no information on HRQoL levels prior to the cancer
diagnosis. It is likely that those cancer survivors with a co-
morbid CVD at cancer diagnosis started out with a lower
HRQoL prior to cancer diagnosis, as CVD is negatively related
to HRQoL [18,19]. It may be the negative impact of having a
CVD at cancer diagnosis that is responsible for the lower
HRQoL levels at follow-up. In other words, the negative
impact of cancer and its treatment on HRQoL might, in fact,
be similar for both survivors with and without co-morbid
CVD at cancer diagnosis. Alternatively, there may be a syner-
gistic effect of having a co-morbid CVD and then additionally
getting cancer and being treated for it. Hence, the impact of
co-morbid CVD may result in a larger negative impact of
cancer and its treatment on survivors’ HRQoL. Future
research including information on HRQoL levels at the time
of cancer diagnosis; follow-up data on the severity and
development of CVD; and the inclusion of a third sample of
patients with only CVD will provide insight into the individ-
ual and possible synergistic effects of cancer(treatment) and
CVD on HRQoL.
A major strength is the large population-based sample of
cancer survivors with various malignancies and the usage of
the high-quality databases NCR and the PROFILES registry.
This study, therefore, encompasses information across malig-
nancies, with a wide age range, including men and women,
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short and long-term survivors, and survivors treated with a
wide range of treatments. This allowed testing effect modifi-
cations for age, gender, time since cancer diagnosis, and sys-
temic therapy, radiation, and hormone treatment. However,
no detailed information on treatment such as type of medi-
cation or dosage was available. Furthermore, CVD status was
retrieved from the NCR based on medical records which are
generally regarded as reliable and complete sources of infor-
mation on the patient’s past and current health status [26].
Nevertheless, only information on presence of CVD and not
date of diagnosis was registered. Additionally, this is to our
knowledge the first large study that examined the relation
between having co-morbid CVD at cancer diagnosis
and HRQoL.
In conclusion, co-morbid CVD at cancer diagnosis is nega-
tively related to HRQoL among cancer survivors. Most con-
sistent findings were found for global QoL, physical and role
functioning, and the symptoms of fatigue and dyspnea.
Health-care providers should, therefore, pay extra attention
to this vulnerable group of cancer survivors with co-morbid
CVD at cancer diagnosis when it comes to their HRQoL, even
years after cancer treatment is finished. Additionally, more
research focusing on unraveling mechanisms leading up to
these HRQoL impairments is needed. Hence, differences in
received treatment should be further explored, as co-morbid
CVD can interfere with cancer treatment and prognosis [27].
Cancer survivors with co-morbid CVDs may be undertreated
[6]. Furthermore, information on the severity and possible
progression of CVDs should be taken into account as cancer
treatment can be cardiotoxic inducing and worsening
CVD [3,4].
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